Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings (NQ: BPTH )

2.760 -0.240 (-8.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bio-Path Holdings

< Previous 1 2 Next >
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Inc. (NASDAQ: BPTH) Near Top of Volume Charts in Thursday Trading
Via Investor Brand Network
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Clinical Advances Across Multiple Programs with Several Milestones 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... 
Via Newsfile
Bio-Path Holdings Reports Full Year 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells’ Ability to Produce Bcl-2 Protein 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23
Dallas, Texas--(Newsfile Corp. - August 30, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path... 
Via Newsfile
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Advancing to Second Cohort of Phase 1/1b Clinical Trial Evaluating BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23
Dallas, Texas--(Newsfile Corp. - June 2, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... 
Via Newsfile
Bio-Path Holdings Reports First Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 '22
Dallas, Texas--(Newsfile Corp. - April 10, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): The... 
Via Newsfile
Bio-Path Holdings Reports Full Year 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides Clinical and Operational Update
Company Expects to Achieve Several Near-Term Clinical Milestones 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.